The stock of Eleven Biotherapeutics Inc (NASDAQ:EBIO) is a huge mover today! About 724,247 shares traded hands. Eleven Biotherapeutics Inc (NASDAQ:EBIO) has risen 624.24% since March 8, 2016 and is uptrending. It has outperformed by 614.93% the S&P500.
The move comes after 5 months negative chart setup for the $50.31 million company. It was reported on Oct, 11 by Barchart.com. We have $2.03 PT which if reached, will make NASDAQ:EBIO worth $5.03M less.
Analysts await Eleven Biotherapeutics Inc (NASDAQ:EBIO) to report earnings on November, 2.
Eleven Biotherapeutics Inc (NASDAQ:EBIO) Ratings Coverage
Out of 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Eleven Biotherapeutics has been the topic of 4 analyst reports since August 15, 2015 according to StockzIntelligence Inc. As per Wednesday, March 16, the company rating was maintained by Citigroup. Citigroup downgraded the stock to “Neutral” rating in Tuesday, January 19 report. The company was maintained on Saturday, August 15 by Leerink Swann. Leerink Swann downgraded the shares of EBIO in a report on Tuesday, January 19 to “Market Perform” rating.
According to Zacks Investment Research, “Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States.”
Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.62, from 0.38 in 2016Q1. The ratio increased, as 5 funds sold all Eleven Biotherapeutics Inc shares owned while 4 reduced positions. 5 funds bought stakes while 4 increased positions. They now own 2.51 million shares or 36.45% more from 1.84 million shares in 2016Q1.
Reilly Financial Advsr Lc has 100 shares for 0% of their US portfolio. National Bank Of America Corp De last reported 0% of its portfolio in the stock. One Trading Limited Partnership holds 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 600 shares. Vanguard last reported 77,656 shares in the company. Citigroup Inc holds 0% or 600 shares in its portfolio. Guggenheim Cap Limited last reported 0% of its portfolio in the stock. Flagship Ventures 2007 General Partner Ltd Liability Corp, a Massachusetts-based fund reported 1.91 million shares. Blackrock Fund Advisors reported 1,624 shares or 0% of all its holdings. The Ontario – Canada-based Royal Savings Bank Of Canada has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Moreover, Kcg has 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 32,907 shares. Renaissance Ltd Liability holds 118,500 shares or 0% of its portfolio. Two Sigma Ltd Llc last reported 25,428 shares in the company. Susquehanna Grp Llp holds 26,654 shares or 0% of its portfolio. Goldman Sachs Gru last reported 13,343 shares in the company. Geode Cap Mgmt Ltd Limited Liability Company accumulated 0% or 46,637 shares.
More news for Eleven Biotherapeutics Inc (NASDAQ:EBIO) were recently published by: 247Wallst.com, which released: “Can Eleven Biotherapeutics Keep Climbing With This Roche Deal?” on August 16, 2016. Marketwatch.com‘s article titled: “Eleven Biotherapeutics’ stock rockets after milestone payment announcement” and published on July 08, 2016 is yet another important article.
EBIO Company Profile
Eleven Biotherapeutics, Inc., incorporated on February 25, 2008, is a preclinical-stage biopharmaceutical company. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.